Last reviewed · How we verify

LYMPHIR — Competitive Intelligence Brief

LYMPHIR (DENILEUKIN DIFTITOX-CXDL) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD25-directed Cytotoxin [EPC]. Area: Other.

marketed CD25-directed Cytotoxin [EPC] Other Live · refreshed every 30 min

Target snapshot

LYMPHIR (DENILEUKIN DIFTITOX-CXDL) — CITIUS PHARMS.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
LYMPHIR TARGET DENILEUKIN DIFTITOX-CXDL CITIUS PHARMS marketed CD25-directed Cytotoxin [EPC]
Ontak DENILEUKIN DIFTITOX Eisai marketed CD25-directed Cytotoxin [EPC] Interleukin-2 receptor 1999-01-01
Ontak E7777 Eisai marketed CD25-directed Cytotoxin Interleukin-2 receptor 1999-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD25-directed Cytotoxin [EPC] class)

  1. CITIUS PHARMS · 1 drug in this class
  2. Eisai · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LYMPHIR — Competitive Intelligence Brief. https://druglandscape.com/ci/denileukin-diftitox-cxdl. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing